Skip to main content

Past Event
7 February 2019

7:00 p.m. –  8:00 p.m. CET
6:00 p.m. – 7:00 p.m. GMT

United States
1:00 p.m. – 2:00 p.m. EST
12:00 p.m. – 1:00 p.m. CST
11:00 a.m. – 12:00 p.m. MST
10:00 a.m. – 11:00 a.m. PST


  • Anna T. Pinedo
    T +1 212 506 2275
  • David S. Bakst
    T +1 212 506 2551

Additional Speakers

Steve Maletzky, William Blair

Financing Alternatives for Life Sciences Companies

The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Approximately 21.7% of the 2017 IPOs were life sciences companies. Many of these IPOs were preceded by late stage
(or mezzanine) private placements made principally to U.S. institutional investors.

In our webinar, we will focus on:

  • Financing alternatives for pre-IPO companies;
  • The late-stage (or “cross-over”) private placement market;
  • Considering milestones when planning a financing strategy;
  • Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations.
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.